Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 20/20 | 0.87 |
| ▸ | ROCK2 | O75116 | 9/20 | 0.87 |
| ▸ | AKT2 | P31751 | 8/20 | 0.87 |
| ▸ | AKT3 | Q9Y243 | 8/20 | 0.87 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.87 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.85 |
| ▸ | LATS1 | O95835 | 2/20 | 0.85 |
| ▸ | PRKCB | P05771 | 2/20 | 0.85 |
| ▸ | RET | P07949 | 2/20 | 0.85 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.85 |
| ▸ | PRKCA | P17252 | 2/20 | 0.85 |
| ▸ | PRKACA | P17612 | 2/20 | 0.85 |
| ▸ | PRKACB | P22694 | 2/20 | 0.85 |
| ▸ | GRK2 | P25098 | 2/20 | 0.85 |
| ▸ | CLK1 | P49759 | 2/20 | 0.85 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.85 |
| ▸ | LIMK2 | P53671 | 2/20 | 0.85 |
| ▸ | PRKAG1 | P54619 | 2/20 | 0.85 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.85 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL386815 | 0.93 | AKT1 (1.00) | AKT1ROCK2AKT2AKT3KCNH2 | |
| SCHEMBL386814 | 0.93 | AKT1 (1.00) | AKT1ROCK2AKT2AKT3KCNH2 | |
| SCHEMBL391114 | 0.93 | AKT1 (1.00) | AKT1ROCK2AKT2AKT3KCNH2 | |
| Capivasertib SCHEMBL31360985 | 0.92 | AKT1 (1.00) | AKT1ROCK2AKT2AKT3KCNH2 | |
| Capivasertib SCHEMBL390244 | 0.92 | AKT1 (1.00) | AKT1ROCK2AKT2AKT3KCNH2 | |
| Capivasertib SCHEMBL391382 | 0.92 | AKT1 (1.00) | AKT1ROCK2AKT2AKT3KCNH2 | |
| Capivasertib SCHEMBL390243 | 0.92 | AKT1 (1.00) | AKT1ROCK2AKT2AKT3KCNH2 | |
| SCHEMBL391567 | 0.92 | AKT1 (1.00) | AKT1ROCK2AKT2AKT3KCNH2 | |
| Capivasertib SCHEMBL29557103 | 0.92 | AKT1 (1.00) | AKT1ROCK2AKT2AKT3KCNH2 | |
| SCHEMBL390328 | 0.92 | AKT1 (1.00) | AKT1ROCK2AKT2AKT3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200261588-A1 | INTERMEDIATE DRUG WITH SYNERGISTIC ANTICANCER ACTIVITY AND POLYETHYLENE GLYCOL-COUPLED SYNERGISTIC ANTICANCER DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | CHONGQING UPGRA BIOLOGICAL SCI. & TECH., LTD. (CN) | 2020-08-20 | — | — | US | disclosed |
| WO-2019173516-A1 | SERINE THREONINE KINASE (AKT) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2019-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200261588-A1 | INTERMEDIATE DRUG WITH SYNERGISTIC ANTICANCER ACTIVITY AND POLYETHYLENE GLYCOL-COUPLED SYNERGISTIC ANTICANCER DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | WEE1, WEE2, SLC11A2 | AKT1 2476/4885ROCK2 3354/4885AKT2 2479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.